Wird geladen...
Bardoxolone methyl: drug development for diabetic kidney disease
Bardoxolone methyl activates the Keap1/Nrf2 system that plays an important role in defense responses against oxidative stress. Importantly, bardoxolone methyl has demonstrated increases in estimated glomerular filtration rate (eGFR) in patients with diabetic kidney disease (DKD) in clinical studies....
Gespeichert in:
| Veröffentlicht in: | Clin Exp Nephrol |
|---|---|
| Hauptverfasser: | , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
Springer Singapore
2020
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7497696/ https://ncbi.nlm.nih.gov/pubmed/32594372 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10157-020-01917-5 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|